Syndax Pharmaceuticals logo

Syndax Pharmaceuticals

SNDX | NASDAQ
Chart Builder DCF Calculator
$9.13
-$0.32 (-3.39%)
At close: Nov 16, 2026, 4:00 PM ET
$9.20
+$0.07 (+0.77%)
After-hours: Nov 16, 2026, 7:54 PM ET
-3.39%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
50.5
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #278/1021 (Top 27%)

Key Statistics

Market Data

Market Cap $821.96M
1D Range
9.06 9.48
52W Range
9.06 25.15

Valuation (TTM)

PE -3.85
PB -47.84
EV/EBITDA -8.25

Valuation (NTM)

Forward PE 269.11
Forward PEG 0.13
Price Target $35.00
Loading financial charts...

Profile

Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, curren...

Sector Healthcare
Industry Biotechnology
Employees 298
IPO Date Mar 2, 2016
Fiscal Year January - December

Latest News

Syndax Pharmaceuticals, Inc. (SNDX) Q3 2026 Earnings Call Transcript

14 days ago · seekingalpha.com

Syndax Pharmaceuticals, Inc. (SNDX) Q3 2026 Earnings Call Transcript
What Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings Call

14 days ago · marketbeat.com

What Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings Call
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Beats Revenue Estimates

14 days ago · zacks.com

Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Beats Revenue Estimates
Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer

14 days ago · globenewswire.com

Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer
Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update

14 days ago · globenewswire.com

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update
Syndax's Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases

18 days ago · globenewswire.com

Syndax's Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
Syndax Announces Participation in November Investor Conferences

18 days ago · globenewswire.com

Syndax Announces Participation in November Investor Conferences
Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

22 days ago · zacks.com

Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026

22 days ago · globenewswire.com

Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
Syndax's Revuforj® (revumenib) Named to TIME's Best Inventions of 2026 List

1 month ago · globenewswire.com

Syndax's Revuforj® (revumenib) Named to TIME's Best Inventions of 2026 List

Earnings

Latest Earnings
Nov 2, 2026
EPS
-$0.55
Miss -9.11%
REV
$83.3M
Beat +2.36%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
8
Consensus
Buy
Price Target
$35.00
Upside
+283.35%
Buy (8)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.